PharmNovo

Rwanda
Byumba, Northern Province, Rwanda, SE223 81

Company profile

PharmNovo company profile

PharmNovo's goal is to develop novel Delta Opioid Receptor Agonists that are safe and effective for chronic pain treatment (DORAs). This is a very different target than traditional opioid drugs, which have caused an epidemic of addiction and toxicity. The company addresses the significant unmet medical need for safe and effective chronic pain treatments, which affects up to 30% of the adult population in the United States and Europe.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Revenue range
$0-$1M
Founded
2008-01-01, Year

Headquarters

Postal code
SE223 81
Country code
RW
Continent
Africa

Capital profile

Funding and company signals

Funding rounds
6
Total equity funding
$28.4M
Last funding
Series Unknown / $16.3M / 2024-07-15
Last equity funding
Series Unknown / $16.3M
Investors
5
Lead investors
2
Founders
1
Articles
22

Founders and investors

Founders

Bengt Mentzer

Lead investors

EIC AcceleratorSciety

Investors

Almi InvestEIC AcceleratorKarolinskaPolynom InvestmentSciety